Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 28:9:2050313X211036005.
doi: 10.1177/2050313X211036005. eCollection 2021.

Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab

Affiliations
Case Reports

Malignant pericardial effusion complicated by cardiac tamponade under atezolizumab

Lardinois Benjamin et al. SAGE Open Med Case Rep. .

Abstract

Immune-related adverse events including cardiac toxicity are increasingly described in patients receiving immune checkpoint inhibitors. We described a malignant pericardial effusion complicated by a cardiac tamponade in an advanced non-small cell lung cancer patient who had received five infusions of atezolizumab, a PDL-1 monoclonal antibody, in combination with cabozantinib. The definitive diagnosis was quickly made by cytology examination showing typical cell abnormalities and high fluorescence cell information provided by the hematology analyzer. The administration of atezolizumab and cabozantinib was temporarily discontinued due to cardiogenic hepatic failure following cardiac tamponade. After the re-initiation of the treatment, pericardial effusion relapsed. In this patient, the analysis of the pericardial fluid led to the final diagnosis of pericardial tumor progression. This was afterwards confirmed by the finding of proliferating intrapericardial tissue by computed tomography scan and ultrasound. This report emphasizes the value of cytology analysis performed in a hematology laboratory as an accurate and immediate tool for malignancy detection in pericardial effusions.

Keywords: Pericardial effusion; atezolizumab; cytology; fluorescence; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Body fluid scattergram. WBC differential fluorescence (WDF) scattergram of the patient’s pericardial effusion showed high fluorescent cells (HF-BF# = 0.132 × 109/L). The greater dispersion of these cells reflects a wide heterogeneity of nucleic acid content and internal cell structure (red ellipse). SFL: side fluorescence; SSC: side scatter.
Figure 2.
Figure 2.
Cytological morphology. Cytomorphological analysis on the collected pericardial effusion was carried out after a cytospin and the May–Grünwald–Giemsa staining method. It highlighted giant basophilic cells compared to a normal neutrophil (a). Some cells accumulated numerous morphological characteristics typical of malignancy including multinuclearity (b), nuclear blebs (c), several large irregular nucleoli (d), asymmetrical mitotic figure (e), and images of cannibalism (f). No acute inflammatory cells were visualized. Magnification: 100×.
Figure 3.
Figure 3.
CT scan. Pericardial tumor nodules (blue arrow) were seen on the CT scan performed at further tumor progression 2 months after the acute cardiac failure.

References

    1. Canale ML, Camerini A, Casolo G, et al.. Incidence of pericardial effusion in patients with advanced non-small cell lung cancer receiving immunotherapy. Adv Ther 2020; 37(7): 3178–3184. - PMC - PubMed
    1. Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor–related cardiotoxicity. Circulation 2017; 136(21): 2085–2087. - PubMed
    1. Heinzerling L, Ott PA, Hodi FS, et al.. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016; 4: 50. - PMC - PubMed
    1. Palaskas N, Morgan J, Daigle T, et al.. Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors. Am J Cardiol 2019; 123(8): 1351–1357. - PubMed
    1. Salem J-E, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19(12): 1579–1589. - PMC - PubMed

Publication types